alexa Peak Heart Rates at Extreme Altitudes
Cardiology

Cardiology

Journal of Clinical & Experimental Cardiology

Author(s): Carsten Lundby

Abstract Share this page

We have measured maximal heart rate during a graded maximal bicycle exercise test to exhaustion in five healthy climbers before and during an expedition to Mt. Everest. Maximal heart rates at sea level were 186 (177-204) beats/min-1 at sea level and 170 (169-182) beats/min-1 with acute hypoxia. After 1, 4 and 6 weeks of acclimatization to 5400 m, maximal heart rates were 155 (135-182), 158 (144-182), and 155 (140-183) beats/min-1, respectively. Heart rates of two of the climbers were measured during their attempt to reach the summit of Mt. Everest without the use of supplemental oxygen. The peak heart rates at 8750 m for the two climbers were 142 and 144 beats/min-1, which were similar to their maximal heart rates during exhaustive bicycle exercise at 5400 m, the values being 144 and 148 beats/min-1, respectively. The peak heart rates at 8750 m are in agreement with other field studies, but considerably higher than values reported from hypobaric chamber studies.

This article was published in High Alt Med Biol and referenced in Journal of Clinical & Experimental Cardiology

Relevant Expert PPTs

Relevant Speaker PPTs

  • Gerald J Prud`homme
    Gamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells
    PPT Version | PDF Version
  • Niru Khatiwada
    Treatment adherence among patients undergoing hemodialysis
    PPT Version | PDF Version
  • Anne Stinn
    Deciphering the crystal structure of NF-CU - a novel bispecific antibody for the treatment of acute myeloid leukemia
    PPT Version | PDF Version
  • Ines Bouaziz
    Water treatment containing organic compounds by coupling adsorption and electrochemical degradation at BDD anode: Sawdust adsorption performance for the treatment of dilute phenol solutions
    PPT Version | PDF Version
  • Donald silverberg
    Is correction of iron deficiency a new addition to the treatment of heart failure?
    PPT Version | PDF Version
  • Ahmed Zeidan
    Effects of intravenous iron in chronic kidney disease and heart failure
    PPT Version | PDF Version
  • Franco Vicariotto
    Probiotics in the treatment of vulvovaginal candidiasis and bacterial vaginosis
    PPT Version | PDF Version
  • Hongdong Huang
    CD4+CD25+ Treg cells may be useful for the treatment of IgAN
    PPT Version | PDF Version
  • Rajashree Khot
    Vitamin D deficiency in diabetic peripheral neuropathy: Prevalence, repletion and treatment outcomes
    PPT Version | PDF Version
  • Arshad Islam
    Nanosystems formed by amphiphilic antimony(v) complexes incorporating amphotericin B for the treatment leishmaniasis
    PPT Version | PDF Version
  • Emanuele Corongiu
    Role of percutaneous tibial nerve stimulation in the treatment of neurogenic overactive bladder syndrome.
    PPT Version | PDF Version
  • Wendy peters
    A non-replicating Ad5 vaccine for treatment of HSV-2
    PPT Version | PDF Version
  • Eran Maman
    New treatment modality for massive Rotator Cuff tears
    PDF Version
  • Isac da Silva Ferreira Lima
    Factors related with early treatment for malaria in the Brazilian Amazon: A multivariable approach using a ten-year population-based malaria surveillance database
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords